Verified safety updates from ongoing ocrelizumab clinical trials and post-marketing experience
The Prescribing Information is the primary source of information on the known and potential risks of ocrelizumab for relapsing forms of multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS).
As of March 2022, more than 250,000 patients with RMS and PPMS have started ocrelizumab globally, amounting to a total of more than 535,000 patient-years.1
The following ocrelizumab global safety updates are available. Click below to learn more:
Updated Safety Analysis
Safety Topics
Post-marketing Commitments
Ocrelizumab is indicated for the treatment of:
Report an Adverse Event:
Phone: (888) 835-2555
Hours: 24 hrs/day, 7 days/week
Medical Communications:
Submit a question online
Phone: (800) 821-8590
Hours: Monday - Friday, 5am - 5pm PT
Contact an MSL:
Request follow-up with a Genentech medical science liaison (MSL)
Genentech data on file: March 31, 2022, post-marketing experience; March 2022, clinical trials data cut-off
Genentech data on file: March 31, 2022, post-marketing experience; March 2022, clinical trials data cut-off
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.